Observational analysis shows innovations in targeting signaling pathways may improve outcomes in pulmonary arterial hypertension, indicating a shift from standard treatments.
The discovery of novel signaling pathways-such as the TGF-β superfamily, growth factors, and tyrosine kinases-has advanced the understanding of PAH and opened opportunities for disease-modifying therapies. Targeting these pathways, including BMPR2 restoration, TGF-β inhibition, and tyrosine kinase blockade, has shown encouraging results beyond the vasodilator-focused standard of care. These innovations may reshape PAH management by improving outcomes, and potentially altering disease progression.
No takes yet. Share an insight, caveat, or question.
Ronald Zolty (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: